PMVP PMV Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1699382 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-7.0%
TTM EPS YoY1.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-99.4%
ROA-72.2%
ROIC (approx.)-100.2%
Asset turnover—
Leverage & solvency
Liabilities / assets48.7%
Debt / equity0.00x
Current ratio9.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $69.88M | $58.53M | $55.88M | $51.99M | $36.49M |
| SG&A expense | $16.33M | $26.92M | $24.25M | $25.05M | $21.80M |
| Operating income | -$86.21M | -$85.45M | -$80.13M | -$77.04M | -$58.29M |
| Pretax income | -$79.91M | -$74.81M | -$68.96M | -$73.33M | -$57.82M |
| Income tax | -$2.17M | -$16.10M | $2,000 | -$9,000 | $23,000 |
| Net income | -$77.74M | -$58.71M | -$68.96M | -$73.32M | -$57.85M |
| EBITDA | -$86.07M | -$84.30M | -$78.88M | -$76.72M | -$57.99M |
| EPS (basic) | -1.48 | -1.14 | -1.44 | -1.61 | -1.28 |
| EPS (diluted) | -1.48 | -1.14 | -1.44 | -1.61 | -1.28 |
| Weighted avg. shares (diluted) | 52.54M | 51.58M | 48.01M | 45.59M | 45.14M |
| Banking | |||||
| Net interest income | $6.34M | $10.65M | $11.17M | $3.63M | $449,000 |
| Balance sheet | |||||
| Cash & equivalents | $37.98M | $40.88M | $37.71M | $108.30M | $172.47M |
| Short-term investments | $74.96M | $128.58M | $165.35M | $132.76M | $124.70M |
| Current assets | $115.23M | $175.66M | $207.41M | $247.01M | $301.29M |
| PP&E, net | $237,000 | $409,000 | $10.67M | $10.96M | $3.09M |
| Total assets | $116.56M | $191.29M | $252.15M | $270.31M | $331.57M |
| Current liabilities | $11.41M | $14.37M | $14.03M | $10.83M | $12.22M |
| Total liabilities | $11.85M | $15.21M | $26.46M | $24.28M | $23.01M |
| Shareholders' equity | $104.71M | $176.08M | $225.69M | $246.03M | $308.56M |
| Shares outstanding | 53.33M | 51.94M | 51.45M | 45.77M | 45.43M |
| Cash flow statement | |||||
| Operating cash flow | -$73.58M | -$51.28M | -$55.66M | -$63.76M | -$46.57M |
| Capital expenditure | $29,000 | $655,000 | $962,000 | $7.98M | $1.35M |
| Free cash flow | -$73.61M | -$51.94M | -$56.62M | -$71.74M | -$47.92M |
| Investing cash flow | $70.17M | $53.35M | -$50.55M | -$1.37M | -$143.58M |
| Financing cash flow | $505,000 | $313,000 | $35.58M | $958,000 | $2.02M |
| Depreciation & amortization | $133,000 | $1.14M | $1.26M | $315,000 | $307,000 |
| Stock-based compensation | $5.92M | $8.87M | $12.38M | $10.20M | $5.34M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.